Market Closed -
Nasdaq
16:30:00 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
7.37
USD
|
-1.73%
|
|
+17.54%
|
-15.96%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
824.9
|
976.3
|
670.5
|
315.5
|
1,020
|
1,088
|
-
|
-
|
Enterprise Value (EV)
1 |
824.9
|
976.3
|
670.5
|
315.5
|
1,020
|
1,088
|
1,088
|
1,088
|
P/E ratio
|
-31.6
x
|
-11.8
x
|
-40.3
x
|
-8.42
x
|
23.7
x
|
24.2
x
|
19.8
x
|
15.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
3.93
x
|
2.59
x
|
1.18
x
|
3.17
x
|
3.01
x
|
2.68
x
|
2.28
x
|
EV / Revenue
|
-
|
3.93
x
|
2.59
x
|
1.18
x
|
3.17
x
|
3.01
x
|
2.68
x
|
2.28
x
|
EV / EBITDA
|
-
|
-
|
-
|
80.6
x
|
17.4
x
|
13.7
x
|
12.1
x
|
10.1
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
41.2
x
|
18.2
x
|
12.3
x
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
2.43%
|
5.5%
|
8.14%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
108,828
|
107,521
|
111,010
|
113,500
|
116,358
|
147,604
|
-
|
-
|
Reference price
2 |
7.580
|
9.080
|
6.040
|
2.780
|
8.770
|
7.370
|
7.370
|
7.370
|
Announcement Date
|
20-07-06
|
21-03-08
|
22-02-28
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
248.2
|
258.6
|
267.8
|
321.5
|
361.5
|
406.2
|
477.9
|
EBITDA
1 |
-
|
-
|
-
|
3.914
|
58.48
|
79.63
|
89.77
|
107.6
|
EBIT
1 |
-
|
-45.4
|
-5.035
|
-24.97
|
55.06
|
60.92
|
78.18
|
128
|
Operating Margin
|
-
|
-18.29%
|
-1.95%
|
-9.32%
|
17.13%
|
16.85%
|
19.25%
|
26.78%
|
Earnings before Tax (EBT)
1 |
-
|
-61.54
|
-10.04
|
-29.99
|
30.63
|
57.36
|
77.2
|
127
|
Net income
1 |
-25.58
|
-83.33
|
-16.42
|
-36.78
|
55.8
|
45.27
|
55.8
|
72.99
|
Net margin
|
-
|
-33.57%
|
-6.35%
|
-13.73%
|
17.36%
|
12.52%
|
13.74%
|
15.27%
|
EPS
2 |
-0.2400
|
-0.7700
|
-0.1500
|
-0.3300
|
0.3700
|
0.3040
|
0.3720
|
0.4850
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
24.79
|
59.8
|
88.5
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
7.71%
|
16.54%
|
21.79%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
42.39%
|
75.09%
|
98.59%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
44.43%
|
132.1%
|
158.62%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-07-06
|
21-03-08
|
22-02-28
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
67.41
|
58.89
|
66.88
|
67.69
|
74.38
|
71.68
|
81.26
|
81.71
|
86.83
|
84.71
|
89.36
|
91.91
|
95.52
|
90.9
|
98.7
|
EBITDA
1 |
-
|
-
|
-
|
-0.724
|
7.317
|
5.543
|
14.1
|
17.62
|
21.22
|
18.66
|
19.77
|
19.58
|
20.93
|
18.2
|
23.4
|
EBIT
1 |
3.301
|
-9.3
|
-9.636
|
-7.103
|
1.072
|
-3.381
|
2.788
|
10.82
|
20.41
|
13.2
|
14.96
|
15.84
|
17
|
12.8
|
18
|
Operating Margin
|
4.9%
|
-15.79%
|
-14.41%
|
-10.49%
|
1.44%
|
-4.72%
|
3.43%
|
13.24%
|
23.51%
|
15.58%
|
16.74%
|
17.23%
|
17.8%
|
14.08%
|
18.24%
|
Earnings before Tax (EBT)
1 |
2.107
|
-10.43
|
-10.81
|
-8.373
|
-0.381
|
-4.932
|
1.126
|
9.125
|
13.91
|
11.41
|
14.25
|
15.24
|
16.51
|
12.8
|
18
|
Net income
1 |
0.618
|
-12.08
|
-12.5
|
-10.1
|
-2.11
|
-6.667
|
-0.528
|
6.761
|
44.83
|
9.261
|
11.33
|
11.96
|
12.85
|
9.6
|
13.5
|
Net margin
|
0.92%
|
-20.5%
|
-18.68%
|
-14.92%
|
-2.84%
|
-9.3%
|
-0.65%
|
8.27%
|
51.63%
|
10.93%
|
12.68%
|
13.02%
|
13.46%
|
10.56%
|
13.68%
|
EPS
2 |
0.0100
|
-0.1100
|
-0.1100
|
-0.0900
|
-0.0200
|
-0.0600
|
-
|
0.0600
|
0.3200
|
0.0600
|
0.0760
|
0.0820
|
0.0840
|
0.0600
|
0.0900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-28
|
22-05-03
|
22-08-02
|
22-11-02
|
23-02-28
|
23-05-02
|
23-08-01
|
23-10-30
|
24-02-28
|
24-04-30
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
24.8
|
59.8
|
88.5
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
1.51
|
1.99
|
4.6
|
5
|
-
|
Capex / Sales
|
-
|
-
|
-
|
0.57%
|
0.62%
|
1.27%
|
1.23%
|
-
|
Announcement Date
|
20-07-06
|
21-03-08
|
22-02-28
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Last Close Price
7.37
USD Average target price
12.68
USD Spread / Average Target +72.09% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.96% | 1.09B | | -19.63% | 131M | | -6.89% | 68.14M | | +5.56% | 60.59M | | +10.38% | 59.81M | | -0.60% | 52.24M |
Bio Medical Devices
|